NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

• NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

• NVX-CoV2373 is highly immunogenic in animal models measuring spike protein–specific antibodies, which are antibodies that block the binding of the spike protein to the receptor and wild-type virus neutralizing antibodies.

• High levels of spike protein–specific antibodies with ACE-2 human receptor–binding, domain-blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization.

• In addition, the already high microneutralization titers seen after one dose increased 8-fold with a second dose. High titer microneutralizing antibodies are generally accepted evidence that a vaccine is likely to be protective in humans.

Source:

https://novavax.com/